Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for Apellis Pharmaceuticals (APLS) over the last 10 years, with Dec 2024 value amounting to $8.0 million.

  • Apellis Pharmaceuticals' Gains from Investment Securities rose 3084.89% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 77.66%. This contributed to the annual value of $8.0 million for FY2024, which is 7.11% down from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Gains from Investment Securities is $8.0 million, which was down 7.11% from $8.7 million recorded in FY2023.
  • Apellis Pharmaceuticals' 5-year Gains from Investment Securities high stood at $8.7 million for FY2023, and its period low was $1.3 million during FY2022.
  • Its 3-year average for Gains from Investment Securities is $6.0 million, with a median of $8.0 million in 2024.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Gains from Investment Securities soared by 797.83% in 2020 and then plummeted by 51.85% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $2.9 million in 2020, then decreased by 6.90% to $2.7 million in 2021, then tumbled by 51.85% to $1.3 million in 2022, then surged by 566.46% to $8.7 million in 2023, then fell by 7.11% to $8.0 million in 2024.